Susan Galbraith on AstraZeneca’s Grand Presence at ASH25
Susan Galbraith, Executive Vice President Oncology Haematology R&D at AstraZeneca, shared on LinkedIn:
”It’s been a great few days at ASH25, and I am very proud that AstraZeneca had its largest presence to date, reflecting our haematology research strategy in action.
We shared scientific updates on our T‑cell engager research targeting CD19 and on cell therapy approaches, including our investigational BCMAxCD19 CAR‑T programme.
These efforts are focused on better understanding immune‑based approaches in blood cancers and coming away from ASH I’m encouraged by the science and collaboration I saw in action as we work to advance the next wave of blood cancer care.
For a closer look at some of these scientific developments, Anas Younes the latest article provides more detail.”
All from ASH25 featured in Hemostasis Today.
-
Dec 12, 2025, 14:478 Posts Not to Miss From the ASH 2025 – Marc Carrier
-
Dec 12, 2025, 10:17Alyssa George on Clinical and Economic Impact of a Eptacog Beta
-
Dec 12, 2025, 09:53Ivan Budnik Awarded AHA Postdoctoral Fellowship! Aiming to Improve DVT Long-term Outcomes
-
Dec 12, 2025, 09:34Giles Platford on Baby Big: Plasma-Derived Drug Against Infant Botulism
-
Dec 12, 2025, 09:22Matteo Foschi Presents The New Expert Guidance on Minor Ischemic Stroke
-
Dec 12, 2025, 07:00Umberto Pensato on Cancer and Stroke
-
Dec 12, 2025, 06:48Steve Tuplin on A New Era in Haemophilia A Care: Reflections from ASH25
-
Dec 12, 2025, 06:30Anirban Sen Gupta on Synthetic Platelets
-
Dec 12, 2025, 05:59Gaetan Duport: A New Legislation for Medicines in Europe